Primaty cultures of rat hypothal c neurons were found. to secrete the potent calcium mobiling ad mitogenic peptide Idotbol (EI) and to contain specific ET binding sites with higher t for ET-1 and ET-2 thautET-3.
in the hypothalamus and acts through calcium-mi ET receptors in normal and transformed serry neurons to stimulate GnIIH release. These actions of locally produced ETs upon GnRH-secreting neurns indicate that the vasoconstrictor peptides have the cafacity to regulate neurosecretion and could participate in the hypothalamic control of anterior pituitary function and gonadotropin secretion.
Endothelin (ET) is a 21-amino acid peptide, originally identified as a potent vasoconstrictor produced by endothelial cells and presumably acting as a local hormone (1, 2). The ET family includes several peptides (ET-1, ET-2, and ET-3) that differ from each other by a few amino acids (3, 4) . Such structural differences and the individual binding characteristics and physiological actions ofthe ETs have suggested the existence of several different ET receptor subtypes (4) (5) (6) (7) . Two distinct ET receptor subtypes, A and B (ETA and ETB), have been characterized by molecular cloning as members of the guanine nucleotide-binding regulatory protein-coupled family ofrhodopsin-type receptors (8, 9) . ETA receptors have higher affinity for ET-L and ET-2 than for ET-3, whereas ETB receptors do not discriminate between the three ETs.
ETs have a wide spectrum of pharmacological effects at locations other than blood vessels (5-7), and receptors specific for ET-1 and ET-2 or for ET-3 are present in several tissues including the intestine, heart, lungs, kidney, adrenal gland, pituitary, and brain (10) (11) (12) (13) (14) (15) . The mRNA for ETA receptors is widely distributed in the central nervous system (16, 17) . It has been proposed that ET-1 and ET-3 have different targets in the brain and may have separate functions (18) . It has also been suggested that ET is produced by glial cells and acts upon both glia and neurons in an autocrineparacrine fashion (14) . Two reports have indicated the potential. involvement of ET in neuroendocrine regulation; ET-like immunoreactivity was demonstrated in paraventricular and supraoptic nuclear neurons with terminals in the posterior pituitary gland (19) , and ET-1 was found to stimulate pituitary hormone secretion in vitro (15) .
The present studies have demonstrated specific receptors for 125I-labeled ET-1 in primary cultures offetal hypothalamic cells and in gonadotropin-releasing hormone (GnRH)-secreting neuronal cell lines (20) . Activation of the neural ET receptors is coupled to inositol phospholipid hydrolysis, inositol phosphate production, and release of GnRH. These findings suggest a role for the ET system at the hypothalam- Kd, Bma, ICW, and other parameters were performed as described (22 25 mM Hepes and 0.1% BSA. After a 5-min preincubation in the same medium, ET-1 (100 nM) and ET-3 (100 nM) or solvent (controls) were added and the cells were incubated at 370C for the indicated times. The radioactivity incorporated into the individual or total inositol phosphates was determined as described (23) .
Measurement of Secretory Responses. with 5% C02/95% 02 for 1 hr. and loaded into a temperaturecontrolled 0.5-ml chamber (Endotronics, Minneapolis). Cells were perifused for at least 1 hr before testing at a flow rate of 10 ml/hr to establish a stable baseline. Fractions were collected every 5 min and stored at -20°C prior to RIA. GnRH assay was performed as described (24) old primary cultures was more potently inhibited by ET-1 (IC50 = 1.5 nM) than by ET-3 (IC50 = 27 nM). 1251-labeled ET-1 also bound specifically to the GT1-1 and GT1-7 neuronal cell lines. Fig. 1B (Fig. 2A) . The peak inositol phosphate response to ET-1 was dose-dependent from 10 pM to 300 nM, with an EC50 value of 7-9 nM (Fig. 2B) . ET-1 was more effective than ET-3 in stimulating production of InsP2, Pharmacology: Krsmanovid et al. (Fig. 3A) ; it was also more potent, as shown by the threshold concentrations of 0.1 nM for ET-1 vs. 1.0 nM for ET-3 (Fig. 3B) . ET also increased inositol phosphate production in [3Hlino-sitol-labele "GT1-cells, consistent with its stimulatory effet on nositol phosph*obid hydrolysis. As shown in Fig.  3C , statistically significant increases in InsP2, Ins(1,3,4)P3, and Ins(1,4,5)P3 were observed 2 min after stinudatio with 100 nM ET. Consistent with its receptor binding activity, the amplitude ofthe inositol phosphate response to ET-2 was the highest,-followed by ET-1 and ET-3 (Fig. 3D ).
Smullalobnof GnRH Rdeese by ET. GnRH released from perifuised cultured hypothalamic cells in-a pulsatile manner, with small interjittent spikes and a mean level of -'20 pg/ml. Suchj pulsatility was asboliihed when the extracellular Ca2+ concentration was reduced froom 1.25 mM to 200 iM (data not shown). In 2+week-old cultures perdiused at a flow rate'o 10 ml/hr, a' 15-min pulse of nM ET-3 stimulated a shgrp increase in GlR.H secretion, followed by a prompt decline to the basal level (Fig. 4A) . Similar QnRH responses were elicited by ET-1 in perifused hypothalamic cells (data not shown). In static cultures, both ET-1 (1OnM) and ET-3 (100 nM) increased GnRH release during a 24-hr incubation.. Te amplitude of the response't ET-1 was higher than that to ET-3 (Fig. 4A Right; ET-1 = 41 9 pg/I; ET-3 =29 1 pg/mi; controls = 13 ± 4 pg/fl; P < 0.01). (16, 26) . MacCumber et al. (14) demonstrated the presence of ET mRNA in several tissues including the brain, which contained a 3.7-kilobase transcript (presumably ET-3); they proposed that biosynthesis of ET occurs in glial cells, which could also be targets for ET action (14) . ET-like immunoreactivity has been demonstrated in rat posterior pituitary gland and paraventricular and supraoptic nuclei, with expression of ET-1 mRNA, suggesting the synthesis of ET in these regions (19) .
The presence of ET in these regions and its participation in regulation of the hypothalamo-pituitary system are of potential physiological importance. ET peptides may be involved in the control of vasopressin and oxytocin release from the posterior pituitary (19) and have been shown to promote the release of vasopressin and substance P from hypothalamic slices (27, 28) and of luteinizing hormone, follicle-stimulating hormone, and substance P from pituitary cells (15, 28 
